Posts

Powerhouse proteins protect heart cells from chemothera...

Researchers at the University of Illinois Chicago have identified a process by w...

ECOG-ACRIN adds a new treatment trial to the ComboMATCH...

The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) has enrolled the first patient...

Center for Open Science welcomes Yvette Seger to its Bo...

Charlottesville, VA –The Center for Open Science (COS) is delighted to announce ...

Wide field-of-view metasurface-enhanced scanning lidar ...

Pulsed laser scanning lidar is a core technology for autonomous driving and robo...

Streets recognized by CMS as legitimate locale to deliv...

The Centers for Medicare and Medicaid Services (CMS) officially recognized that ...

BMS expansion into neurodegeneration space with $95 mil...

Bristol Myers Squibb has expanded into the neuroscience sector with its updated ...

Expansion of Novartis’ Beacon of Hope Initiative

Novartis and the Novartis US Foundation have undergone a substantial expansion o...

Twist and Cancer Research Horizons sign antibody librar...

Twist Bioscience and CRUK innovation arm Cancer Research Horizons have signed an...

Novartis snaps up rare disease biotech DTx Pharma in $1...

The acquisition adds an siRNA delivery platform to Novartis’s armament and a pot...

Pieris Pharma lays off 70% of workforce amid company re...

The biotech announced its employee cuts as part of a strategic update partly cau...

Amarin restructures to counter downturn following Vasce...

Amarin Corporation has initiated a company restructuring programme, following a ...

US DoD enlists VitriVax to develop one-shot vaccine for...

B. pseudomallei is resistant to many antibiotics and, without treatment, can be ...

Santhera and Catalyst to market DMD drug vamorolone in ...

The agreement covers licensing rights in North America for Duchenne muscular dys...

Novartis reports 7% rise in Q2 2023 net sales

Novartis has reported net sales of $13.62bn in Q2 of 2023, indicating a 7% rise ...

Advent receives US NIH grant for bronchopulmonary dyspl...

Advent Therapeutics has received a grant worth $3m from the US NIH for expeditin...

Telix adds another trial in its targeted radiation ther...

The Phase I trial evaluates the combination Telix’s targeted radiation therapy w...